Adaptimmune Ebit from 2010 to 2024
| ADAP Stock | USD 1.04 0.02 1.96% |
EBIT | First Reported 2013-06-30 | Previous Quarter -54 M | Current Value -52.1 M | Quarterly Volatility 18.9 M |
Check Adaptimmune Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Adaptimmune Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 5.2 M, Interest Expense of 1.6 M or Selling General Administrative of 37.2 M, as well as many indicators such as Price To Sales Ratio of 2.5, Dividend Yield of 0.0 or PTB Ratio of 4.24. Adaptimmune financial statements analysis is a perfect complement when working with Adaptimmune Therapeutics Valuation or Volatility modules.
Adaptimmune | Ebit |
Latest Adaptimmune Therapeutics' Ebit Growth Pattern
Below is the plot of the Ebit of Adaptimmune Therapeutics Plc over the last few years. It is Adaptimmune Therapeutics' EBIT historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Adaptimmune Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Ebit | 10 Years Trend |
|
Ebit |
| Timeline |
Adaptimmune Ebit Regression Statistics
| Arithmetic Mean | (80,342,313) | |
| Coefficient Of Variation | (77.08) | |
| Mean Deviation | 53,612,486 | |
| Median | (80,661,000) | |
| Standard Deviation | 61,931,870 | |
| Sample Variance | 3835.6T | |
| Range | 154.6M | |
| R-Value | (0.94) | |
| Mean Square Error | 452.6T | |
| R-Squared | 0.89 | |
| Slope | (13,067,698) | |
| Total Sum of Squares | 53697.8T |
Adaptimmune Ebit History
Other Fundumenentals of Adaptimmune Therapeutics
About Adaptimmune Therapeutics Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Adaptimmune Therapeutics income statement, its balance sheet, and the statement of cash flows. Adaptimmune Therapeutics investors use historical funamental indicators, such as Adaptimmune Therapeutics's Ebit, to determine how well the company is positioned to perform in the future. Although Adaptimmune Therapeutics investors may use each financial statement separately, they are all related. The changes in Adaptimmune Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Adaptimmune Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Adaptimmune Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Adaptimmune Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| EBIT | -137.8 M | -144.7 M | |
| EBITDA | -127.9 M | -134.3 M | |
| Ebt Per Ebit | 0.93 | 1.09 | |
| Ebit Per Revenue | (2.28) | (2.39) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectAdditional Tools for Adaptimmune Stock Analysis
When running Adaptimmune Therapeutics' price analysis, check to measure Adaptimmune Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptimmune Therapeutics is operating at the current time. Most of Adaptimmune Therapeutics' value examination focuses on studying past and present price action to predict the probability of Adaptimmune Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptimmune Therapeutics' price. Additionally, you may evaluate how the addition of Adaptimmune Therapeutics to your portfolios can decrease your overall portfolio volatility.